NewAmsterdam Pharma Company N.V. (NAMS) 10-Year Financial Performance & Capital Metrics

NAMS • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

AboutNewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.Show more

Revenue $46M +223.4%
EBITDA -$176M +3.7%
Net Income -$242M -36.5%
EPS (Diluted) -2.56 -19.1%
Gross Margin 100%
EBITDA Margin -386.66% +70.2%
Operating Margin -386.91% +70.2%
Net Margin -530.25% +57.8%
ROE -46.2% +6.2%
ROIC -
Debt/Equity 0.00 +184.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 14.8% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM4.91%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-11.14%

EPS CAGR

10Y-

5Y-

3Y-

TTM-0.97%

ROCE

10Y Avg-24.94%

5Y Avg-24.94%

3Y Avg-28.11%

Latest-33.42%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.71B	5.58	57.41	43.5%	9.32%		1.92%
CORTCorcept Therapeutics Incorporated	3.72B	35.39	28.77	39.94%	14.19%	16.65%	5.26%	0.01
GUTSFractyl Health, Inc. Common Stock	302.14M	1.97	-1.22	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	465.15M	1.28	-2.03	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	260.56M	2.81	-2.87			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	172.89M	2.03	-3.03	-100%		-282.97%		4.17
ALTAltimmune, Inc.	442.41M	4.24	-3.16	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	771.24M	21.51	-3.24		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	102.69M	14.09M	45.56M
Revenue Growth %	-	-	-	-0.86%	2.23%
Cost of Goods Sold+	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	0	102.69M	14.09M	45.56M
Gross Margin %	-	-	1%	1%	1%
Gross Profit Growth %	-	-	-	-0.86%	2.23%
Operating Expenses+	6.63M	34.98M	106.25M	197.06M	221.85M
OpEx % of Revenue	-	-	1.03%	13.99%	4.87%
Selling, General & Admin	1.69M	5.68M	19.51M	37.63M	70.45M
SG&A % of Revenue	-	-	0.19%	2.67%	1.55%
Research & Development	4.94M	28.97M	86.74M	159.42M	151.41M
R&D % of Revenue	-	-	0.84%	11.31%	3.32%
Other Operating Expenses	1	326K	0	0	0
Operating Income+	-6.63M	-34.98M	-3.56M	-182.97M	-176.29M
Operating Margin %	-	-	-0.03%	-12.99%	-3.87%
Operating Income Growth %	-	-4.27%	0.9%	-50.44%	0.04%
EBITDA+	-6.63M	-34.97M	-3.55M	-182.92M	-176.18M
EBITDA Margin %	-	-	-0.03%	-12.98%	-3.87%
EBITDA Growth %	-	-4.27%	0.9%	-50.56%	0.04%
D&A (Non-Cash Add-back)	1.22K	5K	9K	49K	113K
EBIT	-6.63M	-41.37M	-22.35M	-176.91M	-241.6M
Net Interest Income+	851	-411K	-287K	3.42M	16.88M
Interest Income	851	0	0	10.22M	16.88M
Interest Expense	0	411K	287K	6.8M	0
Other Income/Expense	-390.91K	-6.81M	-19.08M	6.06M	-65.31M
Pretax Income+	-7.02M	-41.78M	-22.63M	-176.91M	-241.6M
Pretax Margin %	-	-	-0.22%	-12.56%	-5.3%
Income Tax+	0	0	0	27K	-1K
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-7.02M	-41.78M	-22.63M	-176.94M	-241.6M
Net Margin %	-	-	-0.22%	-12.56%	-5.3%
Net Income Growth %	-	-4.95%	0.46%	-6.82%	-0.37%
Net Income (Continuing)	-7.02M	-41.78M	-22.63M	-176.94M	-241.6M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-1.15	-3.34	-1.11	-2.15	-2.56
EPS Growth %	-	-1.9%	0.67%	-0.94%	-0.19%
EPS (Basic)	-1.15	-3.34	-1.11	-2.15	-2.56
Diluted Shares Outstanding	17.75M	17.75M	18.97M	82.16M	94.36M
Basic Shares Outstanding	17.75M	17.75M	18.97M	82.16M	94.36M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.87M	66.96M	477.98M	346.79M	863.41M
Cash & Short-Term Investments	1.37M	60.38M	467.73M	340.45M	834.19M
Cash Only	1.37M	60.38M	467.73M	340.45M	771.74M
Short-Term Investments	0	0	0	0	62.45M
Accounts Receivable	0	0	0	1.88M	21.3M
Days Sales Outstanding	-	-	-	48.73	170.67
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	4.88M	2.07M	0	0
Total Non-Current Assets+	138M	1.03M	518K	306K	1.21M
Property, Plant & Equipment	0	216.08K	154K	101K	673K
Fixed Asset Turnover	-	-	666.84x	139.50x	67.70x
Goodwill	0	0	0	0	0
Intangible Assets	0	0	208K	170K	534K
Long-Term Investments	138M	0	0	0	0
Other Non-Current Assets	0	816.56K	156K	35K	0
Total Assets+	139.87M	67.99M	478.5M	347.1M	864.62M
Asset Turnover	-	-	0.21x	0.04x	0.05x
Asset Growth %	-	-0.51%	6.04%	-0.27%	1.49%
Total Current Liabilities+	236.52K	11.24M	36.06M	49.9M	106.92M
Accounts Payable	162.48K	7.07M	11.85M	16.92M	4.74M
Days Payables Outstanding	-	-	-	-	-
Short-Term Debt	0	0	0	0	246K
Deferred Revenue (Current)	0	0	0	1000K	1000K
Other Current Liabilities	74.04K	0	18.02M	15.96M	91.03M
Current Ratio	7.90x	5.96x	13.26x	6.95x	8.08x
Quick Ratio	7.90x	5.96x	13.26x	6.95x	8.08x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	12.17M	126.24K	12.37M	8.81M	202K
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	126.24K	60K	0	202K
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	12.17M	0	12.31M	7.79M	0
Total Liabilities	12.41M	11.36M	48.43M	58.7M	107.12M
Total Debt+	0	186.51K	126K	60K	448K
Net Debt	-1.37M	-60.19M	-467.6M	-340.39M	-771.29M
Debt / Equity	-	0.00x	0.00x	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-85.10x	-12.39x	-26.91x	-
Total Equity+	127.46M	56.63M	430.07M	288.39M	757.5M
Equity Growth %	-	-0.56%	6.59%	-0.33%	1.63%
Book Value per Share	7.18	3.19	22.68	3.51	8.03
Total Shareholders' Equity	127.46M	56.63M	430.07M	288.39M	757.5M
Common Stock	122.46M	128.51K	10.05M	10.17M	13.44M
Retained Earnings	41.45K	-39.44M	-140.04M	-316.97M	0
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	672.13K	4.42M	4.42M	4.47M
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.34M	-29.51M	10.66M	-141.22M	-158.56M
Operating CF Margin %	-	-	0.1%	-10.02%	-3.48%
Operating CF Growth %	-	-3.02%	1.36%	-14.24%	-0.12%
Net Income	-7.07M	-41.78M	-22.63M	-176.94M	-241.6M
Depreciation & Amortization	1.23K	5K	9K	49K	113K
Stock-Based Compensation	0	1.24M	4.12M	0	33.62M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	376.37K	6.55M	18.8M	29.8M	81.98M
Working Capital Changes	-649.41K	4.47M	10.37M	5.87M	-32.67M
Change in Receivables	0	0	0	4.03M	0
Change in Inventory	0	0	0	0	0
Change in Payables	0	0	0	5.07M	-12.95M
Cash from Investing+	-15.99K	-24K	-221K	-24K	-62.85M
Capital Expenditures	-15.99K	-24K	-221K	-24K	-672K
CapEx % of Revenue	-	-	0%	0%	0.01%
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	13.92M	84.7M	391.9M	8.91M	659.51M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	0	-5.79M	0	14M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-7.36M	-29.54M	10.44M	-141.24M	-159.24M
FCF Margin %	-	-	0.1%	-10.02%	-3.49%
FCF Growth %	-	-3.01%	1.35%	-14.52%	-0.13%
FCF per Share	-0.41	-1.66	0.55	-1.72	-1.69
FCF Conversion (FCF/Net Income)	1.05x	0.71x	-0.47x	0.80x	0.66x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	1K

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-5.51%	-45.4%	-9.3%	-49.25%	-46.2%
Return on Invested Capital (ROIC)	-	-42.82%	-	-	-
Gross Margin	-	-	100%	100%	100%
Net Margin	-	-	-22.04%	-1255.76%	-530.25%
Debt / Equity	-	0.00x	0.00x	0.00x	0.00x
Interest Coverage	-	-85.10x	-12.39x	-26.91x	-
FCF Conversion	1.05x	0.71x	-0.47x	0.80x	0.66x
Revenue Growth	-	-	-	-86.28%	223.37%

Revenue by Segment

	2022
License Revenue	93.5M
License Revenue Growth	-

Frequently Asked Questions

Growth & Financials

NewAmsterdam Pharma Company N.V. (NAMS) reported $35.2M in revenue for fiscal year 2024.

NewAmsterdam Pharma Company N.V. (NAMS) grew revenue by 223.4% over the past year. This is strong growth.

NewAmsterdam Pharma Company N.V. (NAMS) reported a net loss of $221.1M for fiscal year 2024.

Dividend & Returns

NewAmsterdam Pharma Company N.V. (NAMS) has a return on equity (ROE) of -46.2%. Negative ROE indicates the company is unprofitable.

NewAmsterdam Pharma Company N.V. (NAMS) had negative free cash flow of $144.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener